PMID- 30234161
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 13
DP  - 2018
TI  - Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
PG  - 402-409
LID - 10.1515/med-2018-0059 [doi]
AB  - BACKGROUND: There are few effective medications for non-alcoholic steatohepatitis 
      (NASH). We investigated the efficacy of ipragliflozin (selective sodium-glucose 
      cotransporter-2 inhibitor [SGLT2I]) for the treatment of patients with type 2 
      diabetes mellitus (T2DM) complicated by non-alcoholic fatty liver disease 
      (NAFLD). METHODS: We prospectively enrolled patients with T2DM complicated by 
      NAFLD treated at our institutions from January 2015 to December 2016. Patients 
      received oral ipragliflozin (50 mg/day) once daily for 24 weeks. Body composition 
      was evaluated using an InBody720 analyzer. We used transient elastography to 
      measure liver stiffness and the controlled attenuation parameter for the 
      quantification of liver steatosis in patients with NASH. RESULTS: Forty-three 
      patients with T2DM and NAFLD were enrolled (12 with biopsy-proven NASH and 31 
      with NAFLD diagnosed by ultrasonography). After 24 weeks, body weight, hemoglobin 
      A1c (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
      gamma-glutamyl transpeptidase, body fat mass, and steatosis were significantly 
      decreased compared to baseline measurements in patients with NASH. However, 
      muscle mass was not reduced, and liver stiffness showed a statistically 
      insignificant tendency to decrease. NAFLD patients also showed a significant 
      reduction in body weight, HbA1c, AST, and ALT compared to baseline measurements. 
      CONCLUSION: Ipragliflozin may be effective in patients with T2DM complicated by 
      NAFLD.
FAU - Miyake, Teruki
AU  - Miyake T
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Toon, Ehime 791-0295, Japan.
FAU - Yoshida, Sakiko
AU  - Yoshida S
AD  - Department of Internal Medicine, Matsuyama Shimin Hospital, Matsuyama, Ehime, 
      Japan.
FAU - Furukawa, Shinya
AU  - Furukawa S
AD  - Department of Epidemiology and Preventive Medicine, Ehime University Graduate 
      School of Medicine, Toon, Japan.
AD  - Epidemiology and Medical Statistics Unit, Translational Research Center, Ehime 
      University Hospital, Toon, Japan.
FAU - Sakai, Takenori
AU  - Sakai T
AD  - Department of Internal Medicine, Yawatahama General City Hospital, Yawatahama, 
      Japan.
FAU - Tada, Fujimasa
AU  - Tada F
AD  - Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Japan.
FAU - Senba, Hidenori
AU  - Senba H
AD  - Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Japan.
FAU - Yamamoto, Shin
AU  - Yamamoto S
AD  - Department of Lifestyle-related Medicine and Endocrinology, Ehime University 
      Graduate School of Medicine, Toon, Japan.
FAU - Koizumi, Yohei
AU  - Koizumi Y
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Shitsukawa, Toon, Ehime, Japan.
FAU - Yoshida, Osamu
AU  - Yoshida O
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Shitsukawa, Toon, Ehime, Japan.
FAU - Hirooka, Masashi
AU  - Hirooka M
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Shitsukawa, Toon, Ehime, Japan.
FAU - Kumagi, Teru
AU  - Kumagi T
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Shitsukawa, Toon, Ehime, Japan.
FAU - Niiya, Tetsuju
AU  - Niiya T
AD  - Department of Internal Medicine, Matsuyama Shimin Hospital, Matsuyama, Ehime, 
      Japan.
FAU - Miyaoka, Hiroaki
AU  - Miyaoka H
AD  - Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Japan.
FAU - Masanori, Abe
AU  - Masanori A
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Shitsukawa, Toon, Ehime, Japan.
FAU - Matsuura, Bunzo
AU  - Matsuura B
AD  - Department of Lifestyle-related Medicine and Endocrinology, Ehime University 
      Graduate School of Medicine, Toon, Japan.
FAU - Hiasa, Yoichi
AU  - Hiasa Y
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, Shitsukawa, Toon, Ehime, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180914
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC6141887
OTO - NOTNLM
OT  - Non-alcoholic fatty liver disease
OT  - Non-alcoholic steatohepatitis
OT  - Selective sodium-glucose cotransporter-2 inhibitor; Ipragliflozin
OT  - Type 2 diabetes mellitus
COIS- Conflict of interest: The authors report no conflicts of interest in this work.
EDAT- 2018/09/21 06:00
MHDA- 2018/09/21 06:01
PMCR- 2018/09/14
CRDT- 2018/09/21 06:00
PHST- 2018/01/27 00:00 [received]
PHST- 2018/08/09 00:00 [accepted]
PHST- 2018/09/21 06:00 [entrez]
PHST- 2018/09/21 06:00 [pubmed]
PHST- 2018/09/21 06:01 [medline]
PHST- 2018/09/14 00:00 [pmc-release]
AID - med-2018-0059 [pii]
AID - 10.1515/med-2018-0059 [doi]
PST - epublish
SO  - Open Med (Wars). 2018 Sep 14;13:402-409. doi: 10.1515/med-2018-0059. eCollection 
      2018.